Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Taysha Gene Therapies, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/25/2023 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in TAYSHA GENE THERAPIES, INC.
08/25/2023 D Form D - Notice of Exempt Offering of Securities:
08/25/2023 SC 13G TCG Crossover GP I, LLC reports a 5.9% stake in Taysha Gene Therapies, Inc.
08/24/2023 144 Form 144 - Report of proposed sale of securities:
08/24/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome"
08/21/2023 SC 13D/A Manning Paul B reports a 12.6% stake in Taysha Gene Therapies, Inc.
08/18/2023 SC 13D/A Astellas Pharma Inc. reports a 3.9% stake in TAYSHA GENE THERAPIES, INC.
08/14/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/14/2023 8-K Quarterly results
Docs: "Form of Pre-Funded Warrant to Purchase Common Stock",
"Form of Securities Purchase Agreement, by and among Taysha Gene Therapies, Inc. and the Purchasers",
"Taysha Gene Therapies Reports Initial Clinical Data from First Adult Rett Syndrome Patient Dosed in REVEAL Phase 1/2 Trial and Provides Corporate Update with Second Quarter 2023 Financial Results",
"Taysha Gene Therapies Announces $150 Million Private Placement Financing"
08/04/2023 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
07/31/2023 8-K Quarterly results
06/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/19/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Taysha Gene Therapies Presents Preclinical Data on TSHA-102 for Rett Syndrome Demonstrating Cellular Regulation of MeCP2 Expression in Key Mouse Models at the American Society of Gene and Cell Therapy 26 th Annual Meeting"
05/15/2023 8-K Quarterly results
Docs: "Taysha Gene Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update"
05/11/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 ARS Form ARS - Annual Report to Security Holders:
05/08/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
05/08/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
05/04/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
05/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2023 8-K Quarterly results
04/27/2023 PRE 14A Form PRE 14A - Other preliminary proxy statements:
04/27/2023 10-K/A Annual Report for the period ended December 31, 2022 [amend]
04/05/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
03/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/28/2023 10-K Annual Report for the period ended December 31, 2022
03/28/2023 8-K Quarterly results
03/08/2023 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/09/2023 SC 13G/A FMR LLC reports a 5.1% stake in TAYSHA GENE THERAPIES INC
01/31/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy